Skip to content
Screener

BioCryst Pharmaceuticals BCRX Business Segments — Loss on Debt Extinguishment

Similar metrics at other companies

InvenTrust Properties logo
IVTReportable Segment — Loss on Debt Extinguishment
$0
MACOM Technology Solutions logo
MTSIReportable Segment — Loss on Debt Extinguishment
$0
Xenia Hotels & Resorts logo
XHRReportable Segment — Loss on Debt Extinguishment
-$21K
Shift4 Payments logo
FOURReportable Segment — Loss on Debt Extinguishment
$0+100%
US Foods logo
USFDReportable Segment — Loss on Debt Extinguishment
$0+100%
Pacific Biosciences of California logo
PACBReportable Segment — Loss on Debt Extinguishment
$0

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.31B+27.7%
Enterprise value$2.56B+29.8%
P/S2.5×-0.8×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest income(2,434)(2,516)(4,690)(5,540)
Interest expense21,71221,58241,49145,076
Foreign currency (gains) losses(27)6319862
Loss on extinguishment of debt4,1714,171
Other (income) expense, net(260)1,202
Income tax expense1,0791,4012,0832,127
Consolidated net income (loss)$78,395$5,085$(643,417)$5,117
1 The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's business segments — loss on debt extinguishment?
BioCryst Pharmaceuticals (BCRX) reported business segments — loss on debt extinguishment of $0 in Q2 2026.
How has BioCryst Pharmaceuticals's business segments — loss on debt extinguishment changed year-over-year?
BioCryst Pharmaceuticals's business segments — loss on debt extinguishment increased by 100.0% year-over-year, from -$4.17M to $0.
What is the long-term trend for BioCryst Pharmaceuticals's business segments — loss on debt extinguishment?
Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's business segments — loss on debt extinguishment has grown at a -22.7% compound annual growth rate (CAGR), from -$29.02M to -$17.33M.
What does business segments — loss on debt extinguishment mean?
Reflects the financial cost incurred when the company retires debt obligations before their scheduled maturity date. This often includes premiums paid to lenders or the write-off of unamortized debt issuance costs, signaling changes in capital structure strategy.

Ask your AI about BioCryst Pharmaceuticals's business segments — loss on debt extinguishment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude